Innoviva, Inc.
Innoviva is a diversified biopharmaceutical company headquartered in Burlingame, California. It has a royalty portfolio of respiratory medicines partnered with GSK, a hospital-focused critical care and infectious disease business called Innoviva Specialty Therapeutics, and strategic healthcare investments and economic interests in other companies. Innoviva receives royalties from GSK sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Its wholly owned operating platform includes GIAPREZA, XACDURO, XERAVA, ZEVTERA and NUZOLVENCE, medicines for conditions including shock, bacterial pneumonia, complicated abdominal infections and gonorrhea. Innoviva markets some products directly and works with commercial partners in certain regions; it also holds U.S. commercialization rights to ZEVTERA under a license with Basilea. Its strategic assets include a significant stake in Armata Pharmaceuticals.
No SEC Form 4 filings for $INVA in the last 30 days.
See all $INVA insider activity →Innoviva (INVA) reported Q3 EPS of -$1.03, missing estimates by $1.56, with revenue at $106.12M, below the $115.4M consensus. The stock is up 3.66% over 3 months and 3.30% over 12 months. InvestingPro rates its financial health as 'great performance'.
Innoviva, Inc. (INVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth $58.1 million in qua
Innoviva reported Q3 2026 U.S. net product sales of $43.3M, a 45% year-over-year increase. The company expects to meet its 2026 guidance of at least $150M in U.S. net product sales, according to the report.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning INVA (Innoviva, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 3 bearish.
Recent INVA coverage spans earnings and financial news.
Earnings miss and revenue shortfall likely weigh on the stock.
The earnings miss and loss may pressure the stock, while the buyback signals confidence and could provide short‑term support.
Positive sales momentum may support the stock price, but the modest absolute size limits upside.
Analyst upgrade and price target imply potential upside for INVA.
The quarter shows earnings volatility despite capital return, which can pressure near-term sentiment until earnings quality stabilizes.
AlphAI scores every news story that mentions INVA with an AI model for sentiment and relevance, and aggregates insider trades from Innoviva, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Innoviva (INVA) reported Q3 EPS of -$1.03, missing estimates by $1.56, with revenue at $106.12M, below the $115.4M consensus. The stock is up 3.66% over 3 months and 3.30% over 12 months. InvestingPro rates its financial health as 'great performance'.
Innoviva, Inc. (INVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth $58.1 million in qua
Innoviva reported Q3 2026 U.S. net product sales of $43.3M, a 45% year-over-year increase. The company expects to meet its 2026 guidance of at least $150M in U.S. net product sales, according to the report.
Oppenheimer analysts identify FuelCell Energy (FCEL) and Innoviva (INVA) as stocks with significant upside potential. FCEL, with a $24 price target, is seen benefiting from data-center electricity demand, while INVA, with a $35 target, is undervalued in specialty therapeutics. Both stocks are rated Outperform, with potential gains of 42% and 66% respectively.
Innoviva, Inc. (INVA) reported Q2 revenue of $119.59 million, up from $100.28 million a year earlier, but shifted from net income of $63.69 million to a net loss of $83.42 million. Loss per share from continuing operations was $1.14. For six months, revenue rose to $217.59 million and net income to $103.18 million, and the company completed a $66.40 million buyback retiring 4.12% of shares.
Innoviva, Inc. (INVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter
Innoviva Inc. (NASDAQ: INVA) is showing weak near and mid-term sentiment despite a long-term positive outlook. AI models have generated three distinct trading strategies with a notable 36.0:1 risk-reward setup targeting a 9.7% gain against 0.3% risk. The analysis indicates various support and resistance levels across different time horizons, with a strong signal for the long term.
Innoviva, Inc. reported significantly higher fourth-quarter and full-year 2025 revenues and net income, with a sharp increase in EPS from continuing operations, attributed partly to a large non-recurring gain. This earnings strength raises questions about its repeatability and influences Innoviva's investment narrative, with its share price rising but still potentially undervalued. Investors should consider the sustainability of these earnings and the tension between strong past performance and future profit forecasts.
Innoviva (INVA) concluded FY 2025 with strong Q4 revenues and EPS, but its 65.9% net profit margin was significantly boosted by a US$161.6 million one-off gain. This challenges bullish narratives, as analysts predict an earnings decline over the next three years, and the company's five-year annualized earnings have declined by 22.1%. The low P/E ratio of 6.5x, compared to an industry average of 19.9x, is seen by some as reflecting softer long-term trends and non-recurring profits.
Innoviva (INVA) delivered earnings and revenue surprises of +134.78% and +14.78%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
